OptimizeRx (OPRX) Income from Non-Controlling Interests (2021 - 2023)

OptimizeRx has disclosed Income from Non-Controlling Interests across 3 years of filings, most recently posting -$4.2 million for Q2 2023.

• In Q2 2023, Income from Non-Controlling Interests fell 7.12% year-over-year to -$4.2 million; the TTM figure through Jun 2023 stood at -$17.9 million (down 146.91% YoY), while the FY2024 annual figure was $204000.0, up 553.33% from the prior year.
• Income from Non-Controlling Interests came in at -$4.2 million for Q2 2023 at OptimizeRx, up from -$6.4 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $352100.0 in Q2 2021 to a low of -$6.4 million in Q1 2023.
• Average Income from Non-Controlling Interests over 3 years is -$3.0 million, with a median of -$3.8 million recorded in 2022.
• Year-over-year, Income from Non-Controlling Interests plunged 8790.01% in 2022 and slipped 7.12% in 2023.
• Over 3 years, Income from Non-Controlling Interests stood at $39894.0 in 2021, then sank by 8790.01% to -$3.5 million in 2022, then slipped by 20.04% to -$4.2 million in 2023.
• Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$4.2 million in Q2 2023, -$6.4 million in Q1 2023, and -$3.5 million in Q3 2022.